Menu
Recruiting NCT06713772

To Evaluate The Skin Closure Time, Parents' Satisfaction, Post Operative Mental Health, Wound Cosmesis and Wound Complication Of Skin Closure Using Adhesive Glue, Adhesive Tape And Suture In Paediatric Surgery Patients

No phase Interventional Skin Wound

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Dermabond Mini, 0.36ml, Ethicon Johnson and Johnson, Somerville, New Jersey, USA, Steri-StripsTM (3M, St. Paul, Minnesota, USA, Monosyn, B.Braun, 118 Pfieffewiesen, Melsungen, Germany.
Who it may be relevant to
Registry conditions: Skin Wound. Basic parameters: 1 Day — 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Malaysia
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Randomised Controlled Trial To Evaluate The Skin Closure Time, Parents' Satisfaction, Post Operative Mental Health, Wound Cosmesis and Wound Complication Of Skin Closure Using Adhesive Glue, Adhesive Tape And Suture In Paediatric Surgery Patients

Overview

This study is a randomised controlled trial to evaluate the skin closure time, parents' satisfaction, post operative mental health, wound cosmesis and wound complication of skin closure using adhesive glue, adhesive tape and suture in paediatric surgery patients. Primary objective is to compare skin closure time required by using adhesive glue, adhesive tape and suture. Secondary objectives are to compare parents' satisfaction, post operative mental health, wound cosmesis and wound complication of skin closure using adhesive glue, adhesive tape and suture in paediatric surgery patients. This study will be conducted from 26th August 2024 to 31st May 2025. It will take place at Hospital Pakar Kanak-Kanak UKM (HPKK), involving paediatric surgery patients undergoing clean or clean contaminated surgeries. The sample size calculated is 30 per group, a total of 90 patients for three groups. The sampling method used is simple random sampling method. In group A, skin will be closed using adhesive glue (Dermabond Mini, 0.36ml, Ethicon Johnson and Johnson, Somerville, New Jersey, USA). Skin closure in group B will be done using adhesive tape (Steri-StripsTM (3M, St. Paul, Minnesota, USA). In group C, skin will be closed using suture (Monosyn, B.Braun, 118 Pfieffewiesen, Melsungen, Germany) 4/0.

Detailed description

This study is a randomised controlled trial to evaluate the skin closure time, parents' satisfaction, post operative mental health, wound cosmesis and wound complication of skin closure using adhesive glue, adhesive tape and suture in paediatric surgery patients.

Primary objective is to compare skin closure time required by using adhesive glue, adhesive tape and suture. Secondary objectives are to compare parents' satisfaction, post operative mental health, wound cosmesis and wound complication of skin closure using adhesive glue, adhesive tape and suture in paediatric surgery patients.

This study will be conducted from 26th August 2024 to 31st May 2025. It will take place at Hospital Pakar Kanak-Kanak UKM (HPKK), involving paediatric surgery patients undergoing clean or clean contaminated surgeries. Inclusion criteria includes patients aged 18 years or less, clean and clean contaminated surgery, wound length of 1-10cm, surgical wound amenable to closure with the three skin closure techniques. Exclusion criteria includes scrotal or penile incision, contaminated or dirty wound, repeated surgical procedures at the surgical site, wound that is not amenable to primary closure with the three techniques, patient with known allergy to cyanoacrylate, patients receiving chemotherapy, immunosuppression, systemic corticosteroids, or with known malignancy.

The sample size calculated is 30 per group, a total of 90 patients for three groups. The sampling method used is simple random sampling method.

In group A, skin will be closed using adhesive glue (Dermabond Mini, 0.36ml, Ethicon Johnson and Johnson, Somerville, New Jersey, USA). Skin closure in group B will be done using adhesive tape (Steri-StripsTM (3M, St. Paul, Minnesota, USA). In group C, skin will be closed using suture (Monosyn, B.Braun, 118 Pfieffewiesen, Melsungen, Germany) 4/0.

Primary outcome, skin closure time will be measured using stopwatch and documented in unit minutes and seconds. It will include the time taken for dressing application, but will not include the time taken for subcutaneous layer closure.

Secondary outcomes, parents' satisfaction will be measured in three aspects - ease of wound care, parents' feeling regarding wound management and satisfaction on wound cosmesis. These will be measured using Likert's scale at day 7 and 1 month post operation. Patient's post operative mental health will be measured in two aspects, post operative pain and patient's fear towards wound management post operation. Post operative pain will be assessed daily from day 1 to day 7. Visual Analog Scale will be used for patients more than 7 years old, whereas FLACC Scale will be used for patients less than 7 years old. Patient's fear towards wound management post operation will be measured using Children's Fear Scale at day 0 and day 7 post operation. Cosmetic appearance of skin will be assessed by using the Vancouver Scar Scale on the day 7 and 1 month. Wound complication will be assessed using ASEPSIS Score on the day 7 and 1 month post operation.

Data will be analysed using IBM SPSS Statistics Version 29. All continuous data (wound cosmesis, wound complication, post operative pain) will be checked for normality distribution using histogram, bell shape curve, skewness and kurtosis. If it is normally distributed, it will be presented in mean and standard deviation and further analysed and compared among three groups using analysis of variance (ANOVA). If it is not normally distributed, it will be presented in median and IQR and further analysed using Kruskal-Wallis test. P value \< 0.050 is considered statistically significant.

Interventions

  • Device Dermabond Mini, 0.36ml, Ethicon Johnson and Johnson, Somerville, New Jersey, USA
    Dermabond Mini, 0.36ml, Ethicon Johnson and Johnson, Somerville, New Jersey, USA
  • Device Steri-StripsTM (3M, St. Paul, Minnesota, USA
    Steri-StripsTM (3M, St. Paul, Minnesota, USA
  • Device Monosyn, B.Braun, 118 Pfieffewiesen, Melsungen, Germany
    Monosyn, B.Braun, 118 Pfieffewiesen, Melsungen, Germany

Primary outcome measures

  • Skin closure time [Time frame: Day 0]
Secondary outcome measures (5)
  • Parents' satisfaction [Time frame: Day 7 and 1 month post operation]
  • Post operative mental health (Post operative pain) [Time frame: Day 1 to day 7]
  • Post operative mental health (Patient's fear towards wound management post operation) [Time frame: Day 0 and day 7]
  • Wound cosmesis [Time frame: Day 7 and 1 month post operation]
  • Wound complication [Time frame: Day 7 and 1 month post operation]

Eligibility criteria

Inclusion criteria

  • patients aged 18 years or less
  • clean and clean contaminated surgery
  • wound length of 1-10cm
  • surgical wound amenable to closure with the three skin closure techniques

Exclusion criteria

  • scrotal or penile incision
  • contaminated or dirty wound
  • repeated surgical procedures at the surgical site
  • wound that is not amenable to primary closure with the three techniques
  • patient with known allergy to cyanoacrylate
  • patients receiving chemotherapy, immunosuppression, systemic corticosteroids, or with known malignancy

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Malaysia · 1 center
  • HUKM — Cheras

Identifiers

NCT: NCT06713772 · FF-2024-290

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗